The Offer to remain open from Wednesday, August 04, 2021 to Friday, August 06, 2021.
Bids can be made for a minimum of 30 Equity Shares and in multiples of 30 Equity Shares thereafter.
The Initial Public Offer consists of Equity Shares of face value of Rs5 each (“Equity Shares”) of Windlas Biotech Limited comprising a fresh issue aggregating up to Rs1,650 million (the “Fresh Issue”) and an offer for sale of up to 5,142,067 Equity Shares (“Offer for Sale” and together with Fresh Issue, the “Offer”).
The Offer for Sale comprises of up to 1,136,000 Equity Shares by Vimla Windlass (the “Individual Selling Shareholder”) and up to 4,006,067 Equity Shares by Tano India Private Equity Fund II (the “Investor Selling Shareholder” and collectively with Individual Selling Shareholder, the “Selling Shareholders”).
All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank accounts and UPI ID (in case of RIBs using UPI Mechanism), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks (“SCSBs”) or the Sponsor Bank, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process.
SBI Capital Markets Limited, DAM Capital Advisors Limited (Formerly IDFC Securities Limited) and IIFL Securities Limited are the BRLMs to the Offer.
The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on BSE and NSE.